<?xml version="1.0" encoding="utf-8"?>
<!-- generator="FeedCreator 1.7.2-ppt (info@mypapit.net)" -->
<?xml-stylesheet href="http://www.ctaf.org/feed.css" type="text/css"?>
<?xml-stylesheet href="http://www.ctaf.org/feed-rss.xsl" type="text/xsl"?>
<rss version="2.0">
    <channel>
        <title>California Technology Assessment Forum</title>
        <description>California Technology Assessment Forum</description>
        <link>http://www.ctaf.org/</link>
        <lastBuildDate>Sat, 04 Feb 2012 09:17:29 GMT</lastBuildDate>
        <generator>FeedCreator 1.7.2-ppt (info@mypapit.net)</generator>
        <item>
            <title>Bronchial Thermoplasty for the Treatment of Severe Asthma - pending final editing</title>
            <link>http://www.ctaf.org/content/assessment/detail/1381/</link>
            <description><![CDATA[This assessment is pending final editing.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Wed, 19 Oct 2011 15:30:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1381/</guid>
        </item>
        <item>
            <title>Metal on Metal Hip Resurfacing as an alternative to Total Hip Arthroplasty</title>
            <link>http://www.ctaf.org/content/assessment/detail/1375/</link>
            <description><![CDATA[Metal on metal hip resurfacing using the BHR, Cormet 2000, or Conserve Plus devices does not meet CTAF criteria 3-5 for safety, efficacy and improvement in health outcomes for patients as an alternative to total hip arthroplasty.
<br><br>
The CTAF Panel voted unanimously to accept the recommendation.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Wed, 19 Oct 2011 16:00:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1375/</guid>
        </item>
        <item>
            <title>Low Dose Spiral Computerized Tomography (LDSCT) Screening for Lung Cancer</title>
            <link>http://www.ctaf.org/content/assessment/detail/1374/</link>
            <description><![CDATA[The use of LDCT as a screening test for lung cancer in high risk individuals at specialized centers meets CTAF criteria 1-5.
<br><br>
The CTAF Panel voted nine in favor of the recommendation and three opposed.  The motion carried.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Wed, 19 Oct 2011 16:00:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1374/</guid>
        </item>
        <item>
            <title>CTAF Meeting</title>
            <link>http://www.ctaf.org/content/calendar/detail/1310/</link>
            <description></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Thu, 08 Sep 2011 16:15:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/calendar/detail/1310/</guid>
        </item>
        <item>
            <title>CTAF Meeting</title>
            <link>http://www.ctaf.org/content/calendar/detail/1309/</link>
            <description></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Thu, 08 Sep 2011 16:15:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/calendar/detail/1309/</guid>
        </item>
        <item>
            <title>CTAF Meeting</title>
            <link>http://www.ctaf.org/content/calendar/detail/1308/</link>
            <description></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Thu, 08 Sep 2011 16:00:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/calendar/detail/1308/</guid>
        </item>
        <item>
            <title>Aqueous Shunts for the Treatment of Glaucoma</title>
            <link>http://www.ctaf.org/content/assessment/detail/1304/</link>
            <description><![CDATA[It is recommended that use of aqueous shunts for the treatment of glaucoma not adequately controlled by medication and / or laser therapy meets CTAF TA Criterion 1 through 5 for safety, effectiveness and improvement in health outcomes.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Thu, 30 Jun 2011 03:45:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1304/</guid>
        </item>
        <item>
            <title>Home Telemonitoring for the Management of Heart Failure</title>
            <link>http://www.ctaf.org/content/assessment/detail/1303/</link>
            <description><![CDATA[It is recommended that use of home telemonitoring for patients with heart failure does not meet CTAF TA Criterion 3 through 5 for safety, effectiveness and improvement in health outcomes.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Thu, 30 Jun 2011 03:45:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1303/</guid>
        </item>
        <item>
            <title>Cryoballoon Ablation for Atrial Fibrillation</title>
            <link>http://www.ctaf.org/content/assessment/detail/1302/</link>
            <description><![CDATA[It is recommended that cryoablation as a treatment for atrial fibrillation does not meet meets CTAF TA criteria 4 or 5 for improvement in health outcomes.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Thu, 30 Jun 2011 03:45:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1302/</guid>
        </item>
        <item>
            <title>Stereotactic Body Radiation Therapy for the Treatment of Early Stage Non Small Cell Lung Cancer</title>
            <link>http://www.ctaf.org/content/assessment/detail/1301/</link>
            <description><![CDATA[It is recommended that stereotactic body radiation therapy for the treatment of early stage non small cell lung cancer in medically inoperable patients with peripheral lesions meets CTAF criteria 2-5 for safety, effectiveness and improvement in outcomes.  
<br><br>
It is recommended that stereotactic body radiation therapy for the treatment of early stage  non small cell lung cancer in medically inoperable patients with central lesions and medically operable patients  does not meet CTAF TA criteria 2-5, for safety, effectiveness, and improvement in outcomes.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Thu, 30 Jun 2011 03:30:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1301/</guid>
        </item>
        <item>
            <title>Radiofrequency Ablation as a Treatment of Dysplastic Barrett’s Esophagus:  Low Grade Dysplasia</title>
            <link>http://www.ctaf.org/content/assessment/detail/1300/</link>
            <description><![CDATA[RFA for the treatment of BE does not meet CTAF Criteria 4-5 for the treatment of individuals with low grade dysplasia (LGD).]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Thu, 30 Jun 2011 01:45:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1300/</guid>
        </item>
        <item>
            <title>Franklin D. Gilliam, PhD</title>
            <link>http://www.ctaf.org/content/member/detail/1281/</link>
            <description></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Tue, 19 Jul 2011 03:30:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/member/detail/1281/</guid>
        </item>
        <item>
            <title>Vitamin D for the Prevention of Osteoporotic Fractures</title>
            <link>http://www.ctaf.org/content/assessment/detail/1250/</link>
            <description><![CDATA[It is recommended that use of vitamin D combined with calcium meets CTAF TA Criteria 1 through 5 for safety, effectiveness and improvement in health outcomes for the prevention of osteoporotic fractures.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Wed, 16 Feb 2011 18:15:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1250/</guid>
        </item>
        <item>
            <title>Therapeutic Hypothermia Following Cardiac Arrest</title>
            <link>http://www.ctaf.org/content/assessment/detail/1249/</link>
            <description><![CDATA[It is recommended that use of therapeutic hypothermia in comatose adults following cardiac arrest with a first rhythm of ventricular fibrillation or ventricular tachycardia meets CTAF TA Criteria 1 through 5 for safety, effectiveness and improvement in health outcomes.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Wed, 16 Feb 2011 18:15:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1249/</guid>
        </item>
        <item>
            <title>Vertebroplasty as a Treatment of Osteoporotic Compression Fractures</title>
            <link>http://www.ctaf.org/content/assessment/detail/1248/</link>
            <description><![CDATA[It is recommended that vertebroplasty does not meet CTAF criteria 3, 4 or 5 for improvement in health outcomes for the treatment of osteoporotic vertebral compression fractures.]]></description>
            <author>California Technology Assessment Forum</author>
            <pubDate>Wed, 16 Feb 2011 18:15:00 GMT</pubDate>
            <guid>http://www.ctaf.org/content/assessment/detail/1248/</guid>
        </item>
    </channel>
</rss>

